STOCK TITAN
  1. Home
  2. News
  3. IBRX

ImmunityBio, Inc. - IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.

The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.

Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.

ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.

Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.

News

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announced a $320 million royalty financing and equity investment by Oberland Capital, providing financial resources for commercialization efforts and pipeline expansion. The investment is non-dilutive and includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
-
News

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) to participate in the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28-30, 2023. The presentation will be a fireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D. The webcast link for the event will be available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announced promising findings from a study on Memory Cytokine-Enriched Natural Killer cells (M-ceNK) suggesting potential benefits for patients with small cell lung cancer and other neuroendocrine tumors. The study presented at the Society for Immunotherapy of Cancer annual meeting revealed M-ceNK cells' effectiveness in targeting SCLC and other neuroendocrine cancers, indicating a new immunotherapy approach for unresponsive cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
News

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

Rhea-AI Summary
ImmunityBio has announced that the FDA has accepted its resubmission of the BLA for N-803 plus BCG for the treatment of non-muscle-invasive bladder cancer. The FDA has set a PDUFA date of April 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.75%
Tags
clinical trial
-
News

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

Rhea-AI Summary
ImmunityBio has completed the resubmission of its Biologics License Application (BLA) for N-803 (Anktiva®) to the FDA. The resubmission includes updated data on the duration of complete response in BCG-unresponsive and BCG-naïve NMIBC patients. The data shows a prolonged duration of remission in both patient cohorts, with a median duration of CR not yet reached in BCG-unresponsive patients and a median survival of 8.8 years in BCG-naïve patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
News

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities

Rhea-AI Summary
ImmunityBio secures $200 million in financing, improving balance sheet and extending debt maturities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.38%
Tags
none
News

ImmunityBio Names Enrique Diloné as Chief Technology Officer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
none
-
News

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
none
-
News

Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients

Rhea-AI Summary
ImmunityBio, Inc. announced findings from a Phase 1 study showing that allogeneic CIML NK cells used in combination with ImmunityBio's IL-15 superagonist N-803 may induce tumor regression in advanced head-and-neck cancer patients. The study demonstrated the potential for a new treatment approach for the disease in cases that currently have poor prognoses. The results were presented at a conference and showed tumor regression associated with expansion of NK cells with cytolytic activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
clinical trial
News

ImmunityBio to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
conferences

FAQ

What is the current stock price of ImmunityBio (IBRX)?

The current stock price of ImmunityBio (IBRX) is $5.035 as of November 21, 2024.

What is the market cap of ImmunityBio (IBRX)?

The market cap of ImmunityBio (IBRX) is approximately 3.5B.

What does ImmunityBio, Inc. specialize in?

ImmunityBio specializes in immuno-oncology and infectious disease treatments, focusing on activating both the innate and adaptive immune systems.

What are the key product candidates of ImmunityBio?

Key product candidates include n-803, aldoxorubicin, and Anktiva, an IL-15 superagonist antibody-cytokine fusion protein.

Which cancers does ImmunityBio focus on treating?

ImmunityBio focuses on treating bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

What geographical segments does ImmunityBio operate in?

ImmunityBio operates in two geographical segments: the United States and Europe, with key revenue generated from Europe.

What types of therapies is ImmunityBio developing?

ImmunityBio is developing antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies.

How does ImmunityBio's Anktiva work?

Anktiva is an IL-15 superagonist antibody-cytokine fusion protein that enhances the body's immune response against cancer cells.

What recent achievements has ImmunityBio made?

ImmunityBio has initiated pivotal clinical trials and formed strategic partnerships with leading research institutions.

Where can I find the latest news about ImmunityBio?

You can stay informed about ImmunityBio's latest developments by visiting the news section on our website.

What is ImmunityBio's business model?

ImmunityBio is an integrated biotechnology company involved in discovering, developing, and commercializing immuno- and cellular therapies.

How does ImmunityBio contribute to cancer treatment?

ImmunityBio develops therapies that activate NK cells, T cells, tumoricidal macrophages, and memory T cells to enhance the immune system's ability to fight cancer.

Stock IBRX logo
ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

#1567 Ranked by Market Cap
N/A Ranked by Dividends

IBRX Stock Data

3.49B
159.81M
77%
10.11%
7.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO